Our findings demonstrate that LNP‐mediated delivery of base editors can effectively correct AGXT pathogenic mutations and ameliorate disease phenotypes in PH1, providing critical preclinical benchmarks for future clinical translation. The gene discussed is AGXT; the disease is primary hyperoxaluria type 1.